A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun; Elaine Johanna Limkin; Maria Vakalopoulou; Laurent Dercle; Stéphane Champiat; Shan Rong Han; Loïc Verlingue; David Brandão; Andrea Lancia; Samy Ammari; Antoine Hollebecque; Jean‐Yves Scoazec; Aurélien Marabelle; Christophe Massard; Jean‐Charles Soria; Charlotte Robert; Nikos Paragios; Éric Deutsch; Charles Ferté

doi:10.1016/s1470-2045(18)30413-3

Keywords

RadiomicsImmunotherapyMedicineBiomarkerCD8Retrospective cohort studyPD-L1Cancer researchOncologyInternal medicineImmunologyImmune systemRadiologyChemistry

Affiliated Institutions

Related Publications

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Timothy A. Chan , Mark Yarchoan , Elizabeth M. Jaffee +4 more

Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...

2018 Annals of Oncology 2769 citations

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Gang Chen , Alexander C. Huang , Wei Zhang +36 more

Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T ...

2018 Nature 2620 citations

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Alexander I. Spira , Keunchil Park , Julien Mazières +7 more

8010 Background: MPDL3280A (anti-PDL1) has demonstrated promising response rates in NSCLC that correlated with PD-L1 expression on tumor-infiltrating immune cells (IC) and/or tu...

2015 Journal of Clinical Oncology 122 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube , Alison Klein , Julie R. Brahmer +7 more

Abstract Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide pat...

2014 Clinical Cancer Research 2295 citations

Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study

Yanbin Chen , Chuanyong Mu , Jian‐An Huang

Aims and background The programmed death-1-ligand 1 (PD-L1) has been recently suggested to play a pivotal role in the immune evasion of tumors from host immune system. In the st...

2012 Tumori Journal 216 citations

Publication Info

Year: 2018
Type: article
Volume: 19
Issue: 9
Pages: 1180-1191
Citations: 1148
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1148

OpenAlex

Cite This

APA Style

                            
                                
                                    Roger Sun, 
                                
                                    Elaine Johanna Limkin, 
                                
                                    Maria Vakalopoulou
                                
                                et al.
                            
                            (2018). 
                            A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. 
                            The Lancet Oncology
                            , 19
                            (9)
                            , 1180-1191.
                            https://doi.org/10.1016/s1470-2045(18)30413-3
                        

Identifiers

DOI: 10.1016/s1470-2045(18)30413-3